2-3. 日本骨髄バンク 論文業績
＊一元化前後の試料を用いた研究の論文を含みます。
B1. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A,
Akaza T, Kamikawaji N, Kodera Y, Takaku F.
Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic
stem cells from an unrelated donor. Japan Marrow Donor Program.

N Engl J Med. 1998;339(17):1177-85.
B2. Juji T, Watanabe Y, Ishikawa Y, Fujiwara K, Tonami H, Tanaka H, Satake M, Akaza T, Tadokoro K,
Kodera Y, Sasazuki T, Morishima Y, Takaku F.
Human platelet alloantigen (HPA)-5a/b mismatch decreases disease-free survival in unrelated bonemarrow transplantation.

Tissue Antigens. 1999;54(3):229-34.
B3. Oh HB, Kim SI, Park MH, Akaza T, Juji T.
Probability of finding HLA-matched unrelated marrow donors for Koreans and Japanese from the
Korean and Japan Marrow Donor Programs.

Tissue Antigens. 1999;53(4 Pt 1):347-9.
B4. Kodera Y, Morishima Y, Kato S, Akiyama Y, Sao H, Matsuyama T, Kawa K, Sakamaki H, Nakagawa
S, Hirabayashi N, Dohi H, Okamoto S, Hiraoka A, Gondo H, Tsuchida M, O H, Harada M, Asano S,
Juji T, Sasazuki T, Takaku F.
Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan
Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia
and aplastic anemia.

Bone Marrow Transplant. 1999;24(9):995-1003.
B5. Ishikawa Y, Kashiwase K, Okai M, Ogawa A, Akaza T, Morishima Y, Inoko H, Sasazuki T, Kodera Y,
Juji T.
Polymorphisms in the coding region of mtDNA and effects on clinical outcome of unrelated bonemarrow transplantation.

Bone Marrow Transplant. 2001;28(6):603-7.
B6. Ishikawa Y, Kashiwase K, Akaza T, Morishima Y, Inoko H, Sasazuki T, Kodera Y, Juji T.
Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.

Bone Marrow Transplant. 2002;29(7):569-75.
B7. Nishimori M, Yamada Y, Hoshi K, Akiyama Y, Hoshi Y, Morishima Y, Tsuchida M, Fukuhara S,
Kodera Y.
Health-related quality of life of unrelated bone marrow donors in Japan.

Blood. 2002;99(6):1995-2001.
B8. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, Sakamaki H, Ikuta K,
Tsuchida M, Hoshi Y, Morishima Y, Kodera Y.
Outcome of 154 patients with severe aplastic anemia who received transplants from unrelateddonors: the Japan Marrow Donor Program.

Blood. 2002;100(3):799-803.

B9. Okamoto S.
Current status of Japan marrow donor program (JMDP) and its roles in international cooperation.

Int J Hematol. 2002;76 Suppl 1:310-1.
B10.Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, Ishikawa Y, Kato S, Sao H,
Sakamaki H, Kawa K, Hamajima N, Asano S, Kodera Y.
The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving
a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Blood. 2002;99(11):4200-6.
B11.Li S, Kawata H, Katsuyama Y, Ota M, Morishima Y, Mano S, Kulski JK, Naruse T, Inoko H.
Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in
unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci.

Tissue Antigens. 2004;63(4):362-8.
B12.Izutsu K, Kanda Y, Ohno H, Sao H, Ogawa H, Miyazaki Y, Kawa K, Kodera Y, Kato S, Morishima Y,
Hirai H; Japan Marrow Donor Program.
Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan
Marrow Donor Program.

Blood. 2004;103(5):1955-60.
B13.Sakata N, Kawa K, Kato K, Yabe H, Yabe M, Nagasawa M, Mugishima H, Kigasawa H, Tsuchida M,
Akiyama Y, Morisima Y, Kodera Y, Kato S.
Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease:an update of the experience of the Japan Marrow Donor Program.

Int J Hematol. 2004;80(2):174-82.
B14.Kanda Y, Sakamaki H, Sao H, Okamoto S, Kodera Y, Tanosaki R, Kasai M, Hiraoka A, Takahashi S,
Miyawaki S, Kawase T, Morishima Y, Kato S; Japan Marrow Donor Program.
Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelateddonor.

Biol Blood Marrow Transplant. 2005;11(11):881-9.
B15.Akiyama H, Hara M, Hino M, Sao H, Hoshi Y, Ohto H, Kai S.
Second donation of bone marrow: results from the Japan Marrow Donor Program (JMDP).

Bone Marrow Transplant. 2006;37(8):795-6.
B16.Kikuchi T, Naruse TK, Onizuka M, Li S, Kimura T, Oka A, Morishima Y, Kulski

JK, Ichimiya S,

Sato N, Inoko H.
Mapping of susceptibility and protective locifor acute GVHD in unrelated HLA-matched bonemarrow transplantation donors and recipients using 155 microsatellite markers on chromosome 22.

Immunogenetics. 2007;59(2):99-108.
B17.Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S,
Morishima Y, Kodera Y, Harada M; Japan Marrow Donor Program.
Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative
donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow
Donor Program.

Biol Blood Marrow Transplant. 2007;13(1):90-9.
B18.Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, Yamamoto K, Maruya E, Akatsuka Y,
Onizuka M, Sakamaki H, Sao H, Ogawa S, Kato S, Juji T, Sasazuki T, Kodera Y; Japan Marrow
Donor Program.
Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome inleukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.

Biol Blood Marrow Transplant. 2007;13(3):315-28.
B19.Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S,
Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y; Japan Marrow Donor
Program.
Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelateddonor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor
Program.

Br J Haematol. 2007;137(2):142-51.
B20.Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y,
Sasazuki T; Japan Marrow Donor Program.
High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease
and implication for its molecular mechanism.

Blood. 2007;110(7):2235-41.
B21.Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M,
Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y,
Morishima Y; Japan Marrow Donor Program.
Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination
and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR
ligand-mismatched T cell-replete unrelated bone marrow transplantation.

Biol Blood Marrow Transplant. 2008;14(1):75-87.
B22.Kodera Y.
The Japan Marrow Donor Program, the Japan Cord Blood Bank Network and the Asia Blood andMarrow Transplant Registry.

Bone Marrow Transplant. 2008;42 Suppl 1:S6.
B23.Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H,
Hirokawa M, Ohto H, Ashida H, Motoyoshi K; Japan Marrow Donor Program.
Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplantsfrom unrelated donors in the Japan Marrow Donor Program.

Haematologica. 2008;93(11):1686-93.
B24.Ogawa S, Matsubara A, Onizuka M, Kashiwase K, Sanada M, Kato M, Nannya Y, Akatsuka Y,
Satake M, Takita J, Chiba S, Saji H, Maruya E, Inoko H, Morishima Y,
Japan Marrow Donation Program (JMDP).
Exploration of the genetic basis of GVHD by genetic association studies.

Biol Blood Marrow Transplant. 2009;15(1 Suppl):39-41.

Kodera Y, Takehiko S;

B25.Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, Kato S, Sasazuki T, Kodera Y,
Morishima Y; Japan Marrow Donor Program.
HLA mismatch combinations associated with decreased risk of relapse: implications for themolecular mechanism.

Blood. 2009;113(12):2851-8.
B26.Fuji S, Kim SW, Yoshimura K, Akiyama H, Okamoto S, Sao H, Takita J, Kobayashi N, Mori S; Japan
Marrow Donor Program.
Possible association between obesity and posttransplantation complications including infectious
diseases and acute graft-versus-host disease.

Biol Blood Marrow Transplant. 2009;15(1):73-82.
B27.Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Kanda
Y, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor Program.
NKG2D

gene

polymorphism

hasasignificant

impactontransplant

outcomesafter

HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic
malignancies.

Haematologica. 2009;94(10):1427-34.
B28.Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T,
Muramatsu H, Morishima Y, Kodera Y.
Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis
in patients with severe aplastic anemia who received bone marrow transplantation from unrelateddonors: results of matched pair analysis.

Biol Blood Marrow Transplant. 2009;15(12):1603-8.
B29.Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, Inoue M, Koike K, Kawase T,
Ito M, Kurosawa H, Tanizawa A, Tono C, Hamamoto K, Hotta N, Watanabe A, Morishima Y, Kawa K,
Shimada H.
Outcome of 125 children with chronic myelogenous leukemia who received transplants fromunrelated donors: the Japan Marrow Donor Program.

Biol Blood Marrow Transplant. 2010;16(2):231-8.
B30.Morishima S, Ogawa S, Matsubara A, Kawase T, Nannya Y, Kashiwase K, Satake M, Saji H, Inoko
H, Kato S, Kodera Y, Sasazuki T, Morishima Y; Japan Marrow Donor Program.
Impact of highly conserved HLA haplotype on acute graft-versus-host disease.

Blood. 2010;115(23):4664-70.
B31.Tanabe T, Yamaguchi N, Matsuda K, Yamazaki K, Takahashi S, Tojo A, Onizuka M, Eishi Y,
Akiyama H, Ishikawa J, Mori T, Hara M, Koike K, Kawa K, Kawase T, Morishima Y, Amano H,
Kobayashi-Miura M, Kakamu T, Nakamura Y, Asano S, Fujita Y.
Association analysis of the NOD2 gene with susceptibility to graft-versus-hostdisease in a

Japanese population.

Int J Hematol. 2011;93(6):771-8.
B32.Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, Kanda Y, Sao H, Akiyama H,
Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan

Marrow Donor Program.
A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts
transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.

Bone Marrow Transplant. 2011;46(2):238-43.
B33.Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, Morishima Y, Kawa K, Kikuchi A,
Nagatoshi Y, Tanaka J, Ashida T, Hirokawa M, Tsuchida M, Mori S.
Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: areport from Japan Marrow Donor Program.

Bone Marrow Transplant. 2011;46(9):1192-202.
B34.Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue
M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor Program.
A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after
HLA-matched unrelated BMT.

Bone Marrow Transplant. 2011;46(11):1455-63.
B35.Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T,
Morishima Y, Kodera Y; Japan Marrow Donor Program.
Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients withacquired severe aplastic anemia.

Blood. 2011;118(11):3186-90.
B36.Espinoza LJ, Takami A, Nakata K, Yamada K, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura
K, Okamoto S, Inoue M, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor
Program.
Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelatedbone marrow transplantation for myeloid malignancies.

PLoS One. 2011;6(8):e23827.
B37.Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, Kato M, Sanada M,
Morishima Y, Hosokawa K, Sasaki Y, Ohtake S, Ogawa S, Nakao S; Japan Marrow Donor Program.
Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic
anemia.

Blood. 2011;118(25):6601-9.
B38.Espinoza JL, Takami A, Nakata K, Onizuka M, Kawase T, Akiyama H, Miyamura K, Morishima Y,
Fukuda T, Kodera Y, Nakao S; Japan Marrow Donor Program.
A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-hostdisease after unrelated bone marrow transplantation.

PLoS One. 2011;6(10):e26229.
B39.Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V,

Horowitz MM,

Madrigal JA, Morishima Y, Oudshoorn M, Ringden O, Spellman S, Velardi A, Zino E, Petersdorf EW;
International Histocompatibility Working Group in Hematopoietic Cell Transplantation.
Effect of T-cell-epitope matching at

HLA-DPB1 in recipients of unrelated-donor haemopoietic-celltransplantation: a retrospective study.

Lancet Oncol. 2012;13(4):366-74.
B40.Kimura F, Sato K, Akiyama H, Sao H, Okamoto S, Kobayashi N, Hara M, Kawa K, Motoyoshi K;
Japan Marrow Donor Program.
M-CSF attenuates severity of chronic GVHD after unrelated BMT.

Bone Marrow Transplant. 2012;47(3):426-9.
B41.Harkensee C, Oka A, Onizuka M, Middleton PG, Inoko H, Hirayasu K, Kashiwase K, Yabe T,
Nakaoka H, Gennery AR, Ando K and MorishimaY; Japan Marrow Donor Program.
Single nucleotide polymorphisms and outcome risk in unrelated mismatched hematopoietic stem
cell transplantation: an exploration study.

Blood. 2012;119(26):6365-72.
B42.Espinoza JL,Takami A, Onizuka M, Morishima Y, Fukuda T, Kodera Y, Akiyama H, Miyamura K,
Mori T, Nakao S; Japan Marrow Donor Program.
Recipient PTPN22 – 1123 C/C genotype predicts acute graft-versus-host disease after HLA fully
matched unrelated bone marrow transplantation for hematologic malignancies.

Biol Blood Marrow Transplant. 2013;19(2):240-6.
B43.Nakata K, Takami A, Espinoza JL, Matsuo K , Morishima Y, Onizuka M , Fukudad T, Kodera Y,
Akiyama H, Miyamura K, Mori T, Nakao S; Japan Marrow Donor Program.
The recipient CXCL10 +1642C>G variation predicts survival outcomes after HLA fully matchedunrelated bone marrow transplantation.

Clin Immunol. 2013;146(2):104-11.
B44.Harkensee C, Oka A, Onizuka M, Middleton PG, Inoko H, Nakaoka H, Gennery AR, Ando K,
Morishima Y; Japan Marrow Donor Programme (JMDP).
Microsatellite

scanning

ofthe

immunogenome

associates

MAPK14

and

ELTD1

with

graft-versus-host disease in hematopoietic stem cell transplantation.

Immunogenetics. 2013;65(6):417-27.
B45.Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, Kato S, Cesbron A,
Tiercy JM, Senitzer D, Velardi A, Petersdorf EW; International Histocompatibility Working Groupin Hematopoietic Cell Transplantation.
Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after
unrelated donor hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant. 2013;19(8):1197-203.
B46.Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M, Yabe T, Murata M, DokiN, Eto T, Mori T, Miyamura K, Sao H, Ichinohe T, Saji H, Kato S, Atsuta Y, Kawa K, Kodera Y,
Sasazuki T; Japan Marrow Donor Program.
Biological significance of HLA locus matching in unrelated donor bone marrow transplantation.

Blood. 2015;125(7):1189-97.
B47.Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Kashiwase K, Morishima Y,
Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Nakao S, Ohtake S, Morishita E.
A donor thrombomodulin gene variation predicts graft-versus-host disease development andmortality after bone marrow transplantation.

Int J Hematol. 2015;102(4):460-70.
B48.Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N, Sugita J, Mori T,
Kurokawa M, Mori SI.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic
Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.

Biol Blood Marrow Transplant. 2017;23(6):938-44.
B49.矢部普正.
造血細胞移植における幹細胞ソースの選択.

臨床血液. 2005;46:399-409.
B50.Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H,
Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y.
Prospectively Isolated Human Bone Marrow Cell-Derived MSCs Support Primitive Human
CD34-Negative Hematopoietic Stem Cells.

Stem Cells. 2015;33(5):1554-65.
B51.Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K,
Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M.
Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic
stem cell transplantation in adult patients with acute lymphoblastic leukemia.

Int J Hematol. 2011;94(5):463-71.
B52.Granell M, Urbano-Ispizua A, Pons A, Aróstegui JI, Gel B, Navarro A, Jansa S, Artells R, Gaya A,
Talarn C, Fernández-Avilés F, Martínez C, Rovira M, Carreras E, Rozman C, Juan M, Yagüe J,
Montserrat E, Monzó M.
Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of
HLA-identical sibling allogeneic stem cell transplantation.

Blood. 2008;112(10):4337-42.
B53.Ozaki Y, Suzuki S, Kashiwase K, Shigenari A, Okudaira Y, Ito S, Masuya A, Azuma F, Yabe T,
Morishima S, Mitsunaga S, Satake M, Ota M, Morishima Y, Kulski JK, Saito K, Inoko H, Shiina T.
Cost-efficient multiplex PCR for routine genotyping of up to nine classical HLA loci in a single
analytical run of multiple samples by next generation sequencing.

BMC Genomics. 2015;16:318.
B54.Suzuki S, Ranade S, Osaki K, Ito S, Shigenari A, Ohnuki Y, Oka A, Masuya A, Harting J, Baybayan
P, Kitazume M, Sunaga J, Morishima S, Morishima Y, Inoko H, Kulski JK, Shiina T.
Reference Grade Characterization of Polymorphisms in Full-Length HLA Class I and II Genes With
Short-Read Sequencing on the ION PGM System and Long-Reads Generated by Single Molecule,
Real-Time Sequencing on the PacBio Platform.

Front Immunol. 2018;9:2294.
B55.Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H,
Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H,
Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA,
Maciejewski JP, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcomeof stem cell transplantation.

Blood. 2017;129(17):2347-2358.
B56.平川経晃,黒澤彩子,田島絹子,

山崎裕介,池田奈未,小島裕人,田中秀則,金森平和,宮村耕一,小寺良尚,福田隆浩,公益財団法人日本骨髄バンク.
骨髄バンクコーディネートの現状.

臨床血液. 2018;59(2):153-160.
B57.三川紫緒, 大和田千桂子, 中世古知昭, 井関徹, 堺田惠美子.
非血縁者間同種造血幹細胞移植における手紙交換の実態と送付に関わる影響因子の解析.

臨床雑誌「内科」. 2019;123(1):149-154.
B58.Kawashima N, Nishiwaki S, Shimizu N, Kamoshita S, Watakabe K, Yokohata E, Kurahashi S,
Ozawa Y, Miyamura K.
Outcomes of strategic alternative donor selection or suspending donor search based on Japan
Marrow Donor Program coordination status.

Int J Hematol. 2018;107(5):551-558.
B59.Nishiwaki S, Miyamura K, Kanda Y, Takanashi M, Uchida N, Fukuda T, Ikegame K, Ohashi K, Eto
T,Ozawa Y, Shiratori S, Iwato K, Matsuoka K, Hidaka M, Ichinohe T, Atsuta Y, Kodera Y, Okamoto
S.
A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experienceof Japan.

Bone Marrow Transplantation. 2020;55:657-660.
B60.Fujiwara S, Ikeda K, Kino S, Tanaka A, Hasegawa Y, Fujino K, Makino S, Matsumoto M, Yokohama
A, Takeshita A, Muroi K.
Clinical significance of autologous blood transfusions in bone marrow harvest from unrelateddonors.

International Journal of Hematology. 2020;111(6):833-839.
B61.黒澤彩子, 田島絹子, 遠峰良美, 吉内一浩, 福田隆浩, 公益財団法人日本骨髄バンク.
骨髄バンクドナーにおける幹細胞提供行動と心理・社会的要因の検討.

日本造血細胞移植学会雑誌.2019;8(2):60-69.
B62.Yamamoto F, Suzuki S, Mizutani A, Shigenari A, Ito S, Kametani Y,Kato S, Marcelo Fernandez-Viña,
Murata M, Morishima S, Morishima Y, Tanaka M, Jerzy K. Kulski, Seiamak Bahram and Shiina T.
Capturing Differential Allele-Level Expression and Genotypes of All Classical HLA Loci and
Haplotypes by a New Capture RNA-Seq Method.

Front. Immunol. 2020;11:941.
B63.藤田直人, 岩戸康治, 松浦裕子, 菅野玲子, 岩佐智恵, 小林正夫.
骨髄バンクドナー最終同意面談担当の経験.

日本造血細胞移植学会雑誌.2021;10(2):102-105.
B64.Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T,
Fujii N, Miyamura K, Mori S, Mori Y, Morishima Y, Yabe H, Kodera Y.
Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank

During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program

Transplantation and Cellular Therapy.2021;27(8):664.e1-e6.

B65.Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R,
Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori S, Mori Y, Morishima Y, Yabe H, Atsuta Y, Kodera Y.
Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantationin the Era of the COVID-19 Pandemic:An Update from the Japan Marrow Donor Program.
Transplantation and Cellular Therapy.2021;27(8):664.e1-e6.
B66.日野雅之, 梅本由香里, 幕内陽介, 岡村浩史, 康秀男, 萩山恵子, 折原勝己, 中尾隆文, 岡田昌也,
魚嶋伸彦, 伊藤満, 薬師神公和, 西川彰則, 石川淳, 水野石一, 石川隆之, 福田隆浩.
WEB を用いた採取可能日情報提供の事前入力によるコーディネート期間短縮の試み.

日本造血・免疫細胞療法学会雑誌.2022;11(2):114-121.
B67.黒澤彩子, 遠峰良美, 吉内一浩, 福田隆浩, 公益財団法人日本骨髄バンク.
非血縁ドナーにおける適合通知受理後の行動と心理・社会的要因の検討：ソーシャルマーケティング手法を用いた面接調査.

日本造血・免疫細胞療法学会雑誌.2022;11(3):169-176.